Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HECTOR: hESC-CMs in Chronic Ischemic Left Ventricular Dysfunction
NCT05068674Phase 1Recruiting
- Start
- Mar 2022
- Primary completion
- Oct 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human embryonic stem cell-derived cardiomyocyte in ischemic cardiomyopathy (ICM) (3 cohorts). Primary endpoint: Maximum Tolerated Dose at 3 years. Started Mar 2022; status: recruiting.
02
Drugs
human embryonic stem cell-derived cardiomyocyte
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT05068674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068674.